NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by Jennison Associates LLC

Jennison Associates LLC raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 17.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 591,556 shares of the medical research company’s stock after buying an additional 89,473 shares during the period. Jennison Associates LLC’s holdings in NeoGenomics were worth $9,571,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NEO. BluePath Capital Management LLC acquired a new stake in NeoGenomics in the third quarter valued at $30,000. WINTON GROUP Ltd acquired a new stake in shares of NeoGenomics during the third quarter worth about $133,000. Corton Capital Inc. acquired a new stake in shares of NeoGenomics during the third quarter worth about $141,000. Aigen Investment Management LP acquired a new stake in shares of NeoGenomics during the third quarter worth about $163,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of NeoGenomics during the third quarter worth about $199,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on NeoGenomics from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Piper Sandler lifted their target price on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. BTIG Research lowered their price target on NeoGenomics from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, December 29th. Finally, The Goldman Sachs Group raised their price target on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.50.

NeoGenomics Stock Performance

Shares of NEO opened at $14.14 on Friday. NeoGenomics, Inc. has a twelve month low of $11.03 and a twelve month high of $21.22. The stock’s 50 day moving average is $15.04 and its two-hundred day moving average is $15.89. The company has a quick ratio of 5.95, a current ratio of 6.20 and a debt-to-equity ratio of 0.57.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The company had revenue of $155.55 million for the quarter, compared to analyst estimates of $152.90 million. On average, equities analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total transaction of $38,701.52. Following the sale, the general counsel now owns 34,866 shares of the company’s stock, valued at approximately $521,595.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.